168 related articles for article (PubMed ID: 9385903)
1. Dose-related hemodynamic and electrocardiographic effects of the calcium promoter BAY y 5959 in the presence or absence of congestive heart failure.
Rousseau MF; Massart PE; van Eyll C; Etienne J; Ahn S; Schaefer HG; Mueck W; Bornemann M; Pouleur H
J Am Coll Cardiol; 1997 Dec; 30(7):1751-7. PubMed ID: 9385903
[TBL] [Abstract][Full Text] [Related]
2. Hemodynamic effects of a calcium channel promoter, BAY y 5959, are preserved after chronic administration in ischemic heart failure in conscious dogs.
Yi GH; Burkhoff D; Zhang H; Zhu SM; Zwas D; Wang J
J Pharmacol Exp Ther; 1998 Aug; 286(2):760-6. PubMed ID: 9694931
[TBL] [Abstract][Full Text] [Related]
3. Lack of desensitization and enhanced efficiency of calcium channel promoter in conscious dogs with heart failure.
Asai K; Uechi M; Sato N; Shen W; Meguro T; Mathier MA; Shannon RP; Vatner SF
Am J Physiol; 1998 Dec; 275(6):H2219-26. PubMed ID: 9843822
[TBL] [Abstract][Full Text] [Related]
4. Hemodynamic effects of intravenous sematilide in patients with congestive heart failure: a class III antiarrhythmic agent without cardiodepressant effects.
Stambler BS; Gottlieb SS; Singh BN; Ramanathan KB; Ogilby JD; Ellenbogen KA
J Am Coll Cardiol; 1995 Dec; 26(7):1679-84. PubMed ID: 7594103
[TBL] [Abstract][Full Text] [Related]
5. Direct myocardial effects of OPC-18790 in human heart failure: beneficial effects on contractile and diastolic function demonstrated by intracoronary infusion with pressure-volume analysis.
MacGowan GA; Haber HL; Cowart TD; Tedesco C; Wu C; Feldman MD
J Am Coll Cardiol; 1998 May; 31(6):1344-51. PubMed ID: 9581731
[TBL] [Abstract][Full Text] [Related]
6. Hemodynamic, neurohumoral, and myocardial energetic effects of pimobendan, a novel calcium-sensitizing compound, in patients with mild to moderate heart failure.
Remme WJ; Kruijssen DA; van Hoogenhuyze DC; Krauss XH; Bartels GL; Storm CJ; de Leeuw PW
J Cardiovasc Pharmacol; 1994 Nov; 24(5):730-9. PubMed ID: 7532750
[TBL] [Abstract][Full Text] [Related]
7. Positive inotropic and vasodilator actions of milrinone in patients with severe congestive heart failure. Dose-response relationships and comparison to nitroprusside.
Jaski BE; Fifer MA; Wright RF; Braunwald E; Colucci WS
J Clin Invest; 1985 Feb; 75(2):643-9. PubMed ID: 3973022
[TBL] [Abstract][Full Text] [Related]
8. Hemodynamic and cardiac effects of the selective T-type and L-type calcium channel blocking agent mibefradil in patients with varying degrees of left ventricular systolic dysfunction.
Rousseau MF; Hayashida W; van Eyll C; Hess OM; Benedict CR; Ahn S; Chapelle F; Kobrin I; Pouleur H
J Am Coll Cardiol; 1996 Oct; 28(4):972-9. PubMed ID: 8837576
[TBL] [Abstract][Full Text] [Related]
9. Hemodynamic, echocardiographic, and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure.
Gheorghiade M; Blair JE; Filippatos GS; Macarie C; Ruzyllo W; Korewicki J; Bubenek-Turconi SI; Ceracchi M; Bianchetti M; Carminati P; Kremastinos D; Valentini G; Sabbah HN;
J Am Coll Cardiol; 2008 Jun; 51(23):2276-85. PubMed ID: 18534276
[TBL] [Abstract][Full Text] [Related]
10. A dose-response study of levosimendan in a porcine model of acute ischaemic heart failure.
Kolseth SM; Wahba A; Kirkeby-Garstad I; Aro S; Nordgaard H; Høydal M; Rognmo Ø; Nordhaug D
Eur J Cardiothorac Surg; 2012 Jun; 41(6):1377-83. PubMed ID: 22219475
[TBL] [Abstract][Full Text] [Related]
11. PCA50941, a new 1,4-dihydropyridine, reverses endothelin-induced cardiogenic shock in the anesthetized goat.
Fernández N; García JL; López MG; García AG; Diéguez G
Life Sci; 1998; 62(21):1933-42. PubMed ID: 9619842
[TBL] [Abstract][Full Text] [Related]
12. Hemodynamic effects of intravenous butopamine in congestive heart failure.
Thompson MJ; Huss P; Unverferth DV; Fasola A; Leier CV
Clin Pharmacol Ther; 1980 Sep; 28(3):324-34. PubMed ID: 7408391
[TBL] [Abstract][Full Text] [Related]
13. [Therapy of acute decompensated heart failure with levosimendan].
Müller K; Peters A; Zeus T; Hennersdorf M; Strauer BE
Med Klin (Munich); 2006 Mar; 101 Suppl 1():119-22. PubMed ID: 16802535
[TBL] [Abstract][Full Text] [Related]
14. Improvement in indexes of diastolic performance in patients with congestive heart failure treated with milrinone.
Monrad ES; McKay RG; Baim DS; Colucci WS; Fifer MA; Heller GV; Royal HD; Grossman W
Circulation; 1984 Dec; 70(6):1030-7. PubMed ID: 6499142
[TBL] [Abstract][Full Text] [Related]
15. Cardiac and hemodynamic effects of intravenous dofetilide in patients with heart failure.
Rousseau MF; Massart PE; van Eyll C; Etienne J; Ahn S; Ghadanfar M; Friedrich T; Pouleur H
Am J Cardiol; 2001 Jun; 87(11):1250-4. PubMed ID: 11377349
[TBL] [Abstract][Full Text] [Related]
16. Hemodynamic properties of a new-generation positive luso-inotropic agent for the acute treatment of advanced heart failure.
Sabbah HN; Imai M; Cowart D; Amato A; Carminati P; Gheorghiade M
Am J Cardiol; 2007 Jan; 99(2A):41A-46A. PubMed ID: 17239704
[TBL] [Abstract][Full Text] [Related]
17. Rationale and design of the hemodynamic, echocardiographic and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure (HORIZON-HF) trial.
Blair JE; Macarie C; Ruzyllo W; Bacchieri A; Valentini G; Bianchetti M; Pang PS; Harinstein ME; Sabbah HN; Filippatos GS; Gheorghiade M;
Am J Ther; 2008; 15(3):231-40. PubMed ID: 18496261
[TBL] [Abstract][Full Text] [Related]
18. Milrinone and dobutamine in severe heart failure: differing hemodynamic effects and individual patient responsiveness.
Colucci WS; Wright RF; Jaski BE; Fifer MA; Braunwald E
Circulation; 1986 Mar; 73(3 Pt 2):III175-83. PubMed ID: 3510774
[TBL] [Abstract][Full Text] [Related]
19. Relative contribution of inotropic and vasodilator effects to amrinone-induced hemodynamic improvement in congestive heart failure.
Konstam MA; Cohen SR; Weiland DS; Martin TT; Das D; Isner JM; Salem DN
Am J Cardiol; 1986 Feb; 57(4):242-8. PubMed ID: 3004184
[TBL] [Abstract][Full Text] [Related]
20. Renal, but not systemic, hemodynamic effects of dopamine are influenced by the severity of congestive heart failure.
Ungar A; Fumagalli S; Marini M; Di Serio C; Tarantini F; Boncinelli L; Baldereschi G; Valoti P; La Cava G; Olianti C; Masotti G; Marchionni N
Crit Care Med; 2004 May; 32(5):1125-9. PubMed ID: 15190961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
